Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Endocrinology and Metabolism ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- American association of clinical endocrinology (AACE) clinical practice guideline for the diagnosis and management of non-alcoholic fatty liver disease in primary care and endocrinology settings.Endocr Pract. 2022; 28: 528-562
- Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease.Gastroenterology. 2021; 161: 1657-1669
- The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases.Hepatology. 2018; 67: 328-357
- Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis.N Engl J Med. 2017; 377: 2063-2072
- Fatty liver through the ages: nonalcoholic steatohepatitis.Endocr Pract. 2022; 28: 204-213
- Nonalcoholic steatohepatitis: mayo clinic experiences with a hitherto unnamed disease.Mayo Clin Proc. 1980; 55: 434-438
- MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver Disease.Gastroenterology. 2020; 158: 1999-2014.e1
- Mechanisms and disease consequences of nonalcoholic fatty liver disease.Cell. 2021; 184: 2537-2564
- Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis.Hepatology. 2017; 65: 1557-1565
- Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort.Gut. 2021; 70: 1375-1382
- Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices.Aliment Pharmacol Ther. 2020; 52: 513-526
- Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort.J Hepatol. 2021; 75: 284-291
- The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis.J Hepatol. 2019; 71: 793-801
- Management of Nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action.Diabetes Care. 2017; 40: 419-430
- A Diabetologist’s Perspective of Non-alcoholic Steatohepatitis (NASH): knowledge gaps and future directions.Liver Int. 2020; 40: 82-88
- Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening.Diabetes Care. 2021; 44: 399-406
- Time to include nonalcoholic steatohepatitis in the management of patients with type 2 diabetes.Diabetes Care. 2020; 43: 275-279
- Nonalcoholic fatty liver disease and fibrosis associated with increased risk of cardiovascular events in a prospective study.Clin Gastroenterol Hepatol. 2020; 18: 2324-2331.e4
- Modulation of insulin resistance in nonalcoholic fatty liver disease.Hepatology. 2019; 70: 711-724
- Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement.Circulation. 2005; 112: 2735-2752
- Effect of weight loss, diet, exercise, and bariatric surgery on nonalcoholic fatty liver disease.Clin Liver Dis. 2016; 20: 339-350
- Role of agents for the treatment of diabetes in the management of nonalcoholic fatty liver disease.Curr Diab Rep. 2020; 20: 59
- The emerging role of glucagon-like peptide-1 receptor agonists for the management of NAFLD.J Clin Endocrinol Metab. 2022; 107: 29-38
- Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.N Engl J Med. 2010; 362: 1675-1685
- Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome.World J Gastroenterol. 2015; 21: 7860-7868
- Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis.JAMA. 2021; 326: 2031-2042
Article info
Publication history
Published online: November 17, 2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
